S-0139 (Shionogi).
Shionogi and GlaxoSmithKline (GSK), as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals LLC, are developing S-0139 (SB-737004), an endothelin-A (ETA) antagonist, for the potential treatment of hemorrhagic and ischemic stroke [223386], [252007], [426822], [426830]. By 1999, the compound was in phase II trials in Japan for stroke [348554]; phase II trials were ongoing in March 2002 [446957]. As of May 2000, Shionogi was preparing to develop the drug in the US and Europe [370602]. As of May 2001, a phase I European trial was in preparation [410912]; which was underway by November 2001 [429990]. In July 2001, Shionogi and GSK signed a letter of intent to create a joint venture that was initially to have exclusive rights to develop and commercialize four compounds contributed by Shionogi and one by GSK, including S-0139 14167621. The agreement wasfinalized in October 2001 [426569], [426822]. In August 1999, Lehman Brothers gave S-0139 a 10% probability of reaching the market with an expected launch in 2005. Sales were expected to peak at US $50 million in 2012 [349228].